Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Pharma Sessions

Pharma Sessions artwork

Medical Affairs AI & Omnichannel Strategy: How to Earn Trust and Attention

Jan 22, 202635 minAudio

In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Sean Sheffler-Collins, Director of Scientific Communications and Content at Astellas Pharma, to discuss how Medical Affairs is evolving to meet HCPs' needs through omnichannel communication strategies, accessible and engaging scientific data, and technology-enabled solutions like digital microsites and AI analysis. Pharma Sessions is hosted by Jonathan Kaskey Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/ Or join the Pharma Sessions Substack: www.pharmasessions.substack.com

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

SPEAKER_00I think that the doctors are viewing the MSL as a sort of a colleague. I mean, obviously it's a colleague who works for the drug company, but it's someone they can have that open discussion with. They can discuss things that are not primarily just based on the label of the medication itself, but they can talk about the whole story of the data and they can also talk about how it relates to other options and have a more frank, honest discussion about where it fits in the broader context.

SPEAKER_00Whereas I think with a rep, they're only allowed to talk what's in the prescribing information, and that's it.

SPEAKER_01Hello, hello, and welcome to Pharma Sessions, a place for pharmaceutical leaders to come and learn from each other. I'm your host, Jonathan Kaske. Technology and market trends are bringing change at an ever accelerating rate, and no person, team, or company can afford to be left behind. Here, we dive into the strategies and tactics that our guests use to tackle these challenges and create new opportunities and how you can do the same in your own organization.

SPEAKER_01Welcome on today's episode of Pharma Sessions. I'm thrilled to have Sean Scheffler-Collins. Sean's currently in Global MetAffairs at Estellis and has over 13 years of experience in MetAffairs. And I think what's been really interesting about his particular background is working on both the agency side and now on the pharma side. So on this episode, we're going to explore how Metaffairs is evolving to meet healthcare professionals' needs. We're going to talk about omnichannel communication strategies, creating accessible and engaging scientific data, tech enablement.

SPEAKER_01I'm sure a lot of other good stuff as well. But before we get started, just a reminder that the views here are ours and not reflective of our respective companies. So with that, welcome to the show, Sean. Thanks so much. Really excited to be with you. Absolutely. Well, thank you. It's a beautiful Monday morning. I always like to start with a little bit of an icebreaker. It helps get to know people. So tell me, what have you had to eat so far today?

SPEAKER_00All I've had today is an apple and some coffee.

SPEAKER_01So this is a universal theme, is that Metafairs people always skimp on the food, but never the caffeine. What what do you think that means?

SPEAKER_00I have three kids at home, so I need all the caffeine I can get these days. Absolutely.

SPEAKER_01It sounds like the reverse of the airplane uh oxygen mass where you make sure their needs are met and then you take care of your own.

SPEAKER_00Yep, for sure.

SPEAKER_01Um excellent. Okay, cool. So let's just jump right in. Tell me a little bit about your background. What drew you into medical affairs and SciCom in the first place?

SPEAKER_00Sure. I went to uh graduate school in neuroscience. And during my graduate work, I realized that I was interested in sort of moving away from the lab bench. And I was trying to think about what do I enjoy about science? And I realized that it was the communication, the scientific storytelling, and I guess was what I was really interested in. I think I also wanted to be a writer at an early age, and so it's sort of an interesting combination of being able to write and do science at the same time.

SPEAKER_00I love that. Were you a big reader growing up? Yeah, absolutely. Big reader, and I like doing creative writing classes and did some poetry classes in college and things. I like to think of some of this as storytelling, even though it's very detailed and specific.

SPEAKER_01Yeah, well, it's I mean, there's so much talk about the importance of storytelling in all sorts of communications and how much more memorable it is to tell a good story, where of course, with science you need the data to bag it up, but people remember the message long after they forget the specifics of the statistics in there.

SPEAKER_00Absolutely. And I I think one of the things I also was hopefully able to do is to be I was always a very concise writer. So I think that's also sort of helped me that I want to get to the point and as you said, sort of remember the messages, not everything, not who told it to you, but that sort of planting those key nuggets in your mind.

SPEAKER_01I feel like there's that famous quote that is attributed to all sorts of different people. I don't know if it's just an internet thing where it's like, I apologize I would have made the message shorter if I had more time, right? But some people say Pascal, some people say Benjamin Franklin. I don't actually know. But I think it's a really interesting concept to think about, particularly in SciCom, and and you know, even as you're thinking about omni-channel stuff, what's the current viewpoint on how long or how much attention you can get from doctors?

SPEAKER_01And and how do you prioritize, I guess, brevity versus the depth of the message?

SPEAKER_00We only get a couple minutes of someone's full attention, so that is really key. And I know I've thought like when we've made a mechanism of action video or something else, that it's we all spend all that time reading things, watching videos, but it's really only that first minute or two where you have their attention. And you know, one of the things I've also been thinking about is my my brother is sort of a musician. He was saying how with Spotify things have changed where you no longer have that sort of musical interlude.

SPEAKER_00You get right to the chorus and hope that somebody keeps listening, and then you do the rest of the song. I do think I try and incorporate that as well into what I do, where you really got to start strong because someone's not necessarily gonna keep listening. They may move on to something else. Or, you know, I think also like at a conference where you're walking through, you see different booths, right? And so, you know, there are all these things going for your attention, and for whatever reason, you stop, and if it's not what you want, you just sort of move on.

SPEAKER_00I think that's the ecosystem that we work in now, where there's a lot of voices, a lot of content, and we want to figure out how to how to get someone's attention and give them the right information. Now, if we do have their attention in med affairs, I think we have some advantages on the commercial side. They may have an interaction that's only three to five minutes. But when a doctor is really willing to talk to an MSL, that visit might be a half hour or longer where they can really get into the data and talk about all the details about what type of patient, how you manage them.

SPEAKER_00You know, you can have that full story. You really have to come in with that sort of elevator pitch to get them in the room and have them. My goal at the sort of global level is getting them to come ask for more information. I'm not telling them the whole story. I want them to ask you're sparking curiosity, right?

SPEAKER_01You're almost earning the right to tell the bigger story by. So let me ask this as a question. Is your approach to do that by leading with your biggest, most compelling point and hope that that draws them in? Or are you leading with thought-provoking questions? What is your approach to getting that attention that's gonna cause somebody to spend 30 minutes with a member of your team?

SPEAKER_00It's usually the latter where you're sort of trying to pique their curiosity, with the exception of if we have some sort of really exciting data, and then I'd gonna bloody. Again, sort of like uh a story or something where you know you you're trying to pique their interest to hear more.

SPEAKER_00And so, yeah, as you said, it oftentimes it could be like a leading question or something to just hopefully make them stop and think do I know what I think I know, or could they have more to tell us? Because, you know, I also recognize now I work for a pharma company, so there's only certain types of information an HCP wants to get from the pharma company, and we need to stay in that specific area, which is most easily say more about like what types of information are you referring to?

SPEAKER_00So sometimes the pharma company is a key source of the data itself. We own the clinical data, so that's something that providers know they can come to us and we will give them that sort of clear, unbiased data itself. And most of the time what we know, they want to interpret it themselves, they don't want us to interpret it for them, looking at us necessarily they're looking at us as hard facts, and also in a sort of development pipeline area, the company also has different molecules, different mechanisms of actions, things they're sort of holding on to a lot more of the information.

SPEAKER_00So that's another area where in the pipeline we have some more information to give that could be interesting as well. So there's sort of the two sides of the coin, I guess.

SPEAKER_01I'm thinking about it, what you had said, where an MSL is often getting significant time with the provider, where depending on what data you see, sometimes the commercial interactions are a minute, two minutes, I've seen the number 30 seconds. Is that because the commercial is more viewed as transactional, like, hey, I just need to engage with this person to get my samples? Or is it that's a major difference where depending on what data you see, sometimes the commercial interactions are a minute, two minutes, I've seen the number 30 seconds, right? Is that because the commercial is more viewed as transactional, like, hey, I just need to engage with this person to get my samples, or is it, I mean, what it's a major difference in what you're talking about?

SPEAKER_01What do you attribute that to?

SPEAKER_00I think that in the best case scenario, I think that the doctors are viewing the MSL as a sort of a colleague. I mean, obviously it's a colleague who works for the drug company, but it's someone they can have that open discussion with. They can discuss things that are not primarily just based on the label of the medication itself, but they can talk about the whole story of the data and they can also talk about how it relates to other options and have a more frank, honest discussion about where it fits in the broader context.

SPEAKER_00Whereas I think with a rep, they're only allowed to talk what's in the prescribing information, and that's it. So I think there has been a little bit of a shift of balance where if you're coming to the company to ask a question, most people would rather talk to the scientists than someone who has a different knowledge set. I think that's, you know, the interactions don't happen all the time, but when they do, I think it can be a really positive discussion.

SPEAKER_00And I think that's also where we as a company get a lot of great insights from those interactions to see what are the questions people are asking, what are they thinking about? And we can make decisions of okay, there's a lot of interest in this type of side effect or changing the dosing or these types of patients. Do we have data? Is could we consider a new study? How do we sort of get that detail? So it is a really nice sort of dialogue, it's not just one-sided.

SPEAKER_00I think we we really value those as well, give us a lot of good information um as well. Again, to sort of because I definitely view the Metaphers perspective a lot, is that we're trying to help clinicians decide who's going to succeed on the treatment. We want them to figure out who of my patients could benefit from this. And also if I give them the medication, what do I need to be careful of?

SPEAKER_00What are what are the side effects? What might they experience that I can warn them in advance, or I can change, decide when to have follow-up visits, or decide when I'm going to start at this dose and when I'm going to titrate, or when I may need to come back down. And we're really trying to give them that information so they can make the best decision. Because in any trial, every patient doesn't benefit from the medicine. So we want to try and figure out as much as we can who will benefit and give them that information so they can make the decision.

SPEAKER_01And it sounds like you covered a lot there, but it one of the things that kind of stuck out to me was this idea of looking at the questions themselves that the doctors are asking in order to understand where those gaps in education may be. Kind of trying to glean insights from the stuff coming from the other side, even if they're not specifically saying, hey, you need to show me more data on safety and efficacy. It's if you have a lot of questions about that, that's you understand how to prioritize that.

SPEAKER_01Like if you're thinking about managing a fairly large MSL team, how do you make sure that those are captured or I'm guessing input in somewhat of a standard manner so that you can then start to do that type of analysis?

SPEAKER_00So we get them from different sources. I mean, that the NSLs can put the feedback directly into the CRM system to bring the insights in. But that's a challenge for us, and I'm not sure if it's true. I assume it's probably also true for other companies. We're truly a global company, but the company isn't exactly the same around the globe. And you know, different NSLs sometimes are using different software and it's coming in, and we have to figure out the best solution to get those insights and understand them.

SPEAKER_00I know that that is an area where a lot of companies are using some AI to help summarize the information and help them. You know, if we have that some huge spreadsheet that has all the insights that we brought in, what do you do with that? It's a lot of data. And I think AI, this is another example where I think AI is a really powerful tool, but you still also need to filter it through someone's experience because it's only as good as you treat it and that doesn't yeah.

SPEAKER_01Well, even the idea of using AI or other tech just to clean up and standardize the data coming in, and then there can be analysis however you do that, whether it's it's done by machine or whether it's done by people. But if you're able to say, okay, yeah, in the US, we're using this, this, and this system, and people tend to say this, in Brazil, it might be something totally different. If we can create a standardized input that makes whatever you end up doing with that much easier and more effective.

SPEAKER_00Absolutely. And I think yeah, it is always true that you know, different different places have different concerns and considerations. And we also like within I'm in the global team, but then we've also decided here's some of our priority areas. So, you know, we can't make personalized content for everyone. So we have to say, okay, you know, these are the key countries that we want to work with and make sure when we create content, it's gonna meet their needs.

SPEAKER_00And then we also that's sort of the first pass, and then the second pass would be other places who have other concerns. You know, what can we do to adapt what we have and figure out how to meet their needs as well.

SPEAKER_01If you've been enjoying the conversations here on Pharma Sessions, you should know they're made possible by the team at XSunt. Xunt helps life sciences companies turn complex data into clear, actionable insight. For years, Xunt has made complicated data sets simple to help commercial, medical, and operations teams map what's happening, predict what's next, and make stronger decisions faster. And now there's an added AI layer that makes everything work so much better. I was actually pretty jaded about some of the AI approaches I'd seen, but when XSunt showed me theirs, I actually left my job to come work for them.

SPEAKER_01It's really awesome. So if you want to understand your market, your customers, or your performance with more clarity than ever, check out xunt.com. That's xs-unt.com. All right, let's jump back into the episode. So that's an interesting thinking, and that is kind of a transition point to one thing I wanted to talk about during this conversation is you've had a fairly unique set of experiences working both on the agency side and the pharma side. And I feel like just from conversations I've had with different people, sometimes people are on one side of that fence and the other side of the fence and they're always looking over and saying, Oh, I wonder if the grass is greener on the other side.

SPEAKER_01So I'm gonna ask you about that in general. But I think one of the nice things about being on the vendor side is if let's say you're doing something, I mean, even as you were talking about storytelling earlier, it gives you a chance to get a whole bunch more reps at a given task, for lack of a better term, because you're not just doing it for one drug, but you might be doing the same thing for 10 or 20 different drugs. What is your take on personal history and how that's either helped or slowed you down and on the pharmacide?

SPEAKER_00I found it enormously useful to have had that experience. As you said, I think first of all, understanding, I think I worked at maybe five or so different agencies. So understanding how each agency does things differently, and then working with a lot of different pharma companies working on a lot of different drugs in a lot of different therapy areas, which bringing that experience, I think, is really critical. And, you know, now on the pharma side, I really value the agency's perspective to understand, you know, what are they, how do we sort of get outside of our box?

SPEAKER_00What are other companies doing, or what are other experiences you can bring to that? Because, you know, I think that's really valuable. And, you know, there are some preferences of different types of ACPs, have different ways they like to hear information, and some may be very tech savvy, and some may be very unwilling, you know, very focused on maybe just reading a journal article and you know, figuring out sort of what the preferences are. But I think that experience has been great.

SPEAKER_00And I've certainly you know leaned extremely heavily on my prior experience in order to figure out what's happening. And you know, I think also they're saying going to a Congress is also a great time to walk around and see again, what are other companies doing and see get a sense of what the sort of best practices are. I think that's really helpful. Now, to your early question, I think I didn't understand on the Adrian C side what my job would be like working for the company itself.

SPEAKER_00I think that was a big difference. And yeah, how so? Well, so one difference is that it's I've really only been focused on one product at a time. So everyone is very in-depth knowledge and very focused on one thing and you know not seeing everything else. I think the other thing is that just sort of the decision-making process and how you know how different decisions, choices are being made at that sort of global level and its implications.

SPEAKER_00And I find myself probably on a daily basis really having to justify what I'm doing, how I'm doing it, and why. And I I think I spend a lot more time talking to different stakeholders, like we were talking earlier about different insights, taking the insights and saying the reason that I'm doing this publication or creating this video or creating these slides, we're doing that because of this information we received, and because of this, what's happening in the competitive landscape, or I saw this thing at the ASCO meeting that was really cool.

SPEAKER_00We should do something like that.

SPEAKER_01And I'm right, you know, I'm it makes sense because if you think about it, at an agency, you're essentially working on a project and you don't need to justify why you're working on the project because the the client hired you to do that, versus here, right, you're making decisions strategic and tactical. And so, of course, you have to communicate with the various stakeholders across the organization and up management and everything about why you're making those decisions.

SPEAKER_00But yeah, I think also following through as well, like as you were saying, so I think you can see you know, you sort of complete the task. And that's sort of the end. But now, you know, I complete it, but then I want to ask, okay, to the MFLs that are using it, is this working? What what could I do better? Is there something I did we miss something? Is there what feedback did you get? And sort of continuing to evolve, it's it's more of an iterative collaborative process right in that way.

SPEAKER_01Because you have to live with the results so you're not on to the next client. But I I think it's also kind of cool as you talked about sort of leveraging your agency partners. I mean, I always had this idea this concept in mind of like, okay, if you're just head down and you're doing things the way that Estellus has always done it, you're probably trying to get better every time and you're optimizing on that particular framework. But an agency partner might understand, all right, well, working with 20 or 30 different companies, is this even the best framework to be refining? Right. So I think that there's a lot of benefit there to a strong partnership just because it's a different set of expertise.

SPEAKER_01I mean, that was always my experience when I for a time I was helping a lot of Metafairs companies do virtual ad boards asynchronously. And I was like, I will never have any level of understanding about the science in any way that will be helpful here, but I do know actually how to engage with doctors really, really well because I've seen like 2,500 of these of these things over the last few years. So it's like you just have your particular skill sets, and I feel like part of your job, right, is in bringing in those right people who are experts in their particular patch of everything that you're trying to do.

SPEAKER_00And I think I really value the agencies, you know, to help us innovate is one real area where I think they're have so much better a finger on the pulse. And you know, we sit in, we have processes, and sometimes we have discussions with legal and others and say, Oh, I don't know if we could do that. And then you know, the agencies super humble say, Well, look, here are all the other companies that are doing just that that we work on. Like we had one example creating a microsite for a conference where we could share our our data, and you know, that was something that company was very resistant to, and then colleagues were able to convince them this is a great idea, we should do it.

SPEAKER_00And then immediately they decided, oh, we need to do this to every single, you know, this is the thing we need to do this.

SPEAKER_01Right. So can you tell me more about that? Because that's something people are always interested. Like it's hard sometimes to bring innovation to a pharma company because legitimately it's such a regulated space, right? They have to be super careful. So, how were you able to create the business case to to get, if you want to talk about that one in particular, more at a high level, like to get something new approved?

SPEAKER_00It's having a lot of discussions with the different stakeholders. And as I I was saying earlier, you know, sort of billing the case. So saying, you know, I think one thing that's really persuasive with the legal ethics compliance is when other similar companies are doing something so because they are also facing the same regulation and risk. And so especially if some of the very large companies are doing it, that's a good case where they can consider it.

SPEAKER_00So yeah, building that case, building that argument of here are things that are doing, and then also we're under a lot of pressure to show metrics and value of what we're doing. So, you know, for the instance of the microsite, it's a great way to say, okay, if we just have a poster at a conference, here's an idea of how many people will see it. But we can get the data from the site of how many unique users we have almost instantly.

SPEAKER_00And we can also take people to the site a few days later who weren't able to attend the meeting. We can also, the NSL can can talk to them and they say, Oh, you guys had data, you know, I wasn't able to go for this reason, or I live in Brazil, the conference was in America, and here's the link. Go check out we did. And so it's a great way to collect that information and see who's looking at it and expanding the reach, right? I mean, that's that's another key thing for Metafairs, is we want to reach as many people as we can.

SPEAKER_00That's always our our goal because we don't have a sales objective, we don't have those benchmarks, so we're really trying to reach as many people, and again, hoping that leads them to engage with us in whichever way channel they like, whether it's a website, whether it's reading a paper, meeting with MSL, they're all they're all.

SPEAKER_01This kind of gets into the idea of omni-channel a bit, which is you're hoping to meet people kind of where they live. And in some ways, it's kind of democratizing things. If, as you said, you know, somebody who can't travel to Chicago for Ascoke can see things because you're uh providing that information in a venue that they already attend. So when and when you're thinking about there's so many options for some for you know broad term like omni-channel, are you typically looking at reach data, at some type of analytics around how long people are staying on your message or retaining your message?

SPEAKER_01What types of what types of data are you looking at to sort of understand the best way to to manage all this?

SPEAKER_00I'll give you the caveat that it's an evolving process. But you know, I think number one is the the wreaths, how many people can we get and how much where we're allowed to collect information, where are they coming from? So I again I in the US we can get that data for European countries, it's not possible. So understanding who's looking at it from where, how long can they spend, because I I think there is we're talking before with the MSL, there is if they're only spending a few seconds, they're probably not they're not necessarily getting the message.

SPEAKER_00But if they're staying for a long time, then we feel confident that they what they retain is their own story, but they heard they heard the message. And then I think the other key metric is the follow-up, right? If if they continue to engage with the company in any way, that's our other key thing. So, you know, we we view it as sort of one team with the MSLs, with the field reps. We all have the same, we all have the same clinicians.

SPEAKER_00And we try as hard as we can to be seamless in that so that we're not all bothering the same people. You know, that that's some missteps that have happened in the past where you know, both the MSL and the sales rep are talking to the same doctor. They say, you know, stop sending me emails. I've I've had enough. So, you know, we want to make sure they're engaging with whoever they're comfortable with, whether that's a medical information inquiry, whether it's you know, just looking through our website, whether they want to meet with the MSL, whether they want to talk to rep, whoever I guess our key thing with the omni-channel is just that they're they're continuing to engage with us.

SPEAKER_00Because if they don't, then we I think that's sort of a missed opportunity.

SPEAKER_01Some of that stuff happens for kind of best intentions, right? Where it's like, well, medical and commercial have to be completely firewalled from each other. And then you do end up in a scenario where because you're trying to quote unquote do the right thing, like people are getting inundated because they can't they can't see it. So it's there's definitely a balance that is respectful of the regulatory environment of who of what medical's role is and not having commercial goals tied to them, but also doesn't create a bad experience for providers.

SPEAKER_00Let's yeah, we I feel like we can. We have like one of the things that we've done that I think has been nice at Ocellus is we have we have sort of omni-channel partners that collaborate with both the medical and the commercial teams, and so they're a good point of contact to sort of keep us in communication in the compliant way so that we're we're discussing and we know what each other's doing without breaching any firewalls, but at least there's someone who can see the different paths and make sure that we're we're working together instead of in silos.

SPEAKER_01Yes, that makes a ton of sense. All right, Sean. So we've covered a lot here, and I just want to end with a quick callback because you had talked earlier at the very beginning about writing and about being a reader. What have you read lately that's interesting or that you think is worth sharing? Anything stick with you? That is that's an on-the-spot question. I know.

SPEAKER_00That is a hard question. I might need to pull my list for once. Yeah.

SPEAKER_01You know what's funny? I read on the Kindle, and I like I find myself always forgetting the title of the book that I'm reading because it doesn't because you're not staring at it all the time. But while while you're going, I'll share mine. I just finished a new book by this author who I really like called Gary Steingart. Um, wrote Super Sad True Love Story, was I think like one of his breakout ones, but this one is called Vera or Truth, and it was a really interesting, I guess you could call it dystopian future, although it's leaning more towards dystopian present in in the way that he's he's writing it, but I highly recommend it if you're looking for something that's uh interesting and kind of funny and and very good.

SPEAKER_00I'm reading the anecdote by Karen Russell, which is okay. Been enjoying that, has a little bit of magical realism, which is something that's really uh really fun. I've also been, which is not a new one, but the book less I've been recommending to a lot of people, um which is I really like because it's especially in the these times that are pretty contentious. It's like uh a love story, and I I really, you know, it's something sort of light and very well written. Really like that one.

SPEAKER_00And let me see, the other one. I love Colson Whitehead, so I guess any anything by Colson Whitehead, uh, I I love that sort of like sci-fi dystopian again, magical realism, those are themes that I love. So awesome. Well, thanks. We'll we'll leave it there.

SPEAKER_01But Sean, it was great talking with you today. Yes, I really appreciate it. And that's a wrap on today's episode of Pharma Sessions with me, Jonathan Kaske. If you enjoyed today's conversation, don't forget to hit follow or subscribe and share it with someone else in the pharma world who might need to hear it. For more on pharma trends, career growth, and business strategies, connect with me, Jonathan Kaske, on LinkedIn. Until next time, thanks for listening.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Built to Move: Candel Therapeutics' Agile Path from Trial Results to Launch Readiness

    Nov 4, 202636 minAudio

    Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, sits down with Jonathan to discuss the company's sprint from positive Phase III results to commercial launch. They explore how Candel is redefining the...

    Credit the people on this episode

  2. Data, AI, and the Future of Field Training with Annel Duckels from BMS

    Sep 24, 202617 minAudio

    In this episode, Jonathan sits down with Annel Duckels, who leads worldwide commercialization learning at Bristol Myers Squibb, to talk about modernizing pharma training through data and AI. Annel's unconventional path...

    Credit the people on this episode

  3. Hallway Interviews with Pharma Learning Leaders

    Jul 31, 202639 minAudio

    Pharma Sessions - ACTO Client Summit: Hallway Interviews At ACTO's 2026 client summit in Boston, we pulled some incredible minds out of the hallway for quick, candid conversations about where field excellence, AI, and...

    Credit the people on this episode

  4. Blockchain + AI: The Future of Healthcare Data

    Jul 9, 202633 minAudio

    What happens when you put blockchain underneath AI in healthcare? According to Archita Samant, Head of Data Strategy & Analytics for Global Vaccines at Merck - you finally solve the interoperability problem that's been...

    Credit the people on this episode

  5. The Question Behind the Question - Field Training with Jennifer Muszik

    Jun 8, 202629 minAudio

    What separates a good pharma sales rep from a great one? According to Jennifer Muszik, it's the ability to understand the question behind the question - the real need behind what a customer is asking. In this episode,...

    Credit the people on this episode